Polarean Imaging PLC New System Order (0839Q)
15 February 2019 - 6:00PM
UK Regulatory
TIDMPOLX
RNS Number : 0839Q
Polarean Imaging PLC
15 February 2019
Polarean Imaging Plc
("Polarean" or the "Company")
New System Order with the University of British Columbia
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with a proprietary drug--device combination
product for the magnetic resonance imaging (MRI) market, announces
that it has entered into a contract for the procurement of its
latest polarizer system by the University of British Columbia
www.ubc.ca ("UBC") following the conclusion of UBC's procurement
process.
UBC have received financial support from the Canada Foundation
for Innovation ("CFI") www.innovation.ca/about. CFI have also been
active in supporting pulmonary imaging research using
hyperpolarized (129) Xe in the Toronto area and specifically, the
SickKids Hospital in Toronto.
Richard Hullihen, CEO of Polarean, said: "We are excited to
welcome Drs. Sin and Leipsic and the staff of UBC to our expanding
base of collaborative researchers and look forward to assisting
them in achieving the goals of their research programme. UBC has a
long history and pioneering reputation in the field of medical
imaging research and I look forward to providing further updates
regarding our collaboration with UBC as appropriate.
"The Company's management team is excited to see the continued
scientific and clinical evolution of hyperpolarized xenon imaging
in medicine and to assist in providing our equipment to researchers
in order to push these important frontiers."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood
(Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44 (0)7879
741 001
About Polarean (www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution functional
magnetic resonance imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate than current methods. The annual
burden of pulmonary disease in the US is estimated to be over
US$150 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTKMGMZGDMGLZZ
(END) Dow Jones Newswires
February 15, 2019 02:00 ET (07:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2024 to May 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From May 2023 to May 2024